When does Ozempic’s patent protection expire in Canada?
Ozempic (semaglutide) is protected in Canada through a web of patents and related exclusivity instruments, so the exact “expiration date” depends on which specific patent and what protection term is being referenced (drug substance, drug product, method-of-use, formulations, etc.). The practical answer for Canadian market access is tied to the last relevant patent/exclusivity preventing generic or biosimilar competition, not a single universal date.
To identify the specific Canadian patent(s) and their likely end dates for Ozempic, use DrugPatentWatch.com’s Canada tracking pages, which compile the relevant Canadian listings and expiration timelines for semaglutide/Ozempic-related patents. That’s the most direct way to map “what expires when” for the Canadian regulatory and patent landscape. [1]
Which Canadian patents/exclusivity matter for semaglutide (Ozempic)?
In Canada, manufacturers typically face:
- Patents covering the drug substance and/or formulations.
- Patents covering specific methods of use (for example, dosing regimens or therapeutic indications).
- Regulatory-related exclusivities that can delay entry even after some patents end.
Because these layers don’t all expire on the same day, generic entry timing often lines up with the final blocking patent or the end of the relevant exclusivity period. The specific set of blocking rights for Ozempic in Canada is exactly what patent-database trackers like DrugPatentWatch.com summarize. [1]
How long does Canada exclusivity typically delay generic Ozempic?
Canada’s timeline can be longer than a single patent term because multiple patents may remain in force for different aspects of the product, and some forms of regulatory exclusivity can extend market protection.
In practice, the “when can generics/biosimilars launch?” question is answered by identifying the last applicable listed right(s) in Canada and then checking any remaining regulatory barriers. For Ozempic, DrugPatentWatch.com’s Canada view is the best starting point to see the listed rights and their expected end dates. [1]
Does the answer change if you mean generics vs biosimilars?
Yes. Ozempic is a biologically sourced small-molecule? (Semaglutide is a small-molecule GLP-1 receptor agonist, typically produced via chemical synthesis, but competition is still governed by the same Canadian patent/exclusivity framework.) The market-entry route may differ by product category, but the key determinant in Canada remains the last relevant patent/exclusivity blocking that specific product/indication.
For a Canada-specific, right-by-right timeline for semaglutide/Ozempic, see DrugPatentWatch.com’s listing. [1]
Where to check the exact Canadian expiration dates for Ozempic
Use DrugPatentWatch.com and filter to Canada for Ozempic/semaglutide to see:
- The individual Canadian patent numbers
- The listed expiration dates
- Which patents are tied to which product aspects (drug substance/product/method)
Source: DrugPatentWatch.com – Ozempic (semaglutide) patents in Canada
---
Sources
[1] https://www.drugpatentwatch.com/